ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0921

SAPhigh T Peripheral Helper Cells Are a Novel Subset Associated with Lupus Nephritis

Yevgeniya Gartshteyn1, Leila Khalili2, Laura Geraldino-Pardilla2, Adam Mor3 and Anca Askanase4, 1Columbia University Medical Center, New York, NJ, 2Division of Rheumatology, Columbia University Irving Medical Center, New York, NY, 3Columbia University, New York, NY, 4Columbia University Medical Center, New York, NY

Meeting: ACR Convergence 2023

Keywords: Lupus nephritis, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (0899–0933) SLE – Etiology & Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Better understanding of the abnormal immune responses in lupus nephritis (LN) is fundamental to identifying new therapies. We previously reported that the adaptor protein SAP (SLAM Associated Protein) is increased in circulating T follicular helper (TFH) and T peripheral helper (TPH) cells of patients with SLE. SAP regulates T cell function by binding to the co-stimulatory SLAMF (signaling lymphocytic activation molecule family) receptors. SAP and SLAMF are critical for TFH and TPH-dependent B cell maturation into autoantibody-producing plasma cells that characterize SLE pathogenesis. In this work, we set out to evaluate the association between circulating SAPhi T cells and clinical disease activity.

Methods: Peripheral blood mononuclear cells (PBMCs) were isolated using density gradient separation from whole blood. Cells were stained for cell surface markers, followed by permeabilization and staining of intracellular SAP. TFH were defined as CD3+CD4+CD8–PD1hiCXCR5+ and TPH were defined as CD3+CD4+CD8–PD1hiCXCR5–. Other markers included CXCR3, CCR4, CCR6, CD25, CD127 and HLADR. Additionally, we analyzed SAP expression from renal infiltrating LN T cells using the publicly available single-cell RNA sequencing (sc-RNA Seq) Accelerated Medicines Partnership (AMP) in SLE dataset. (Nat Immunol 2019; 20: 902-914.)

Results: PBMCs from 35 patients with SLE (1997 ACR criteria), including 10 patients with LN, were analyzed. The clinical characteristics are presented in Table 1. Mean age was 34±10, 83% were female. Males were more likely to have LN (p=0.03). We found an increase in total SAP-positive CD4 and CD8 T cells in SLE compared with controls (56±16 vs. 41±12 and 53±16 vs 39±10, respectively). In CD4 T cells, the highest SAP expression was in the TPH, detectable in > 90% of TPH cells in some patients. (Fig. 1A) The percent of SAPhiTPH in circulation was associated with SLEDAI-2K (Pearson r=0.5, p=0.01) and showed a trend for inverse association with C3 and C4 levels. SAPhiTPH cells were expanded in SLE patients presenting with flare vs. no flare. A sub-analysis revealed an association with active urine sediment, elevated anti-dsDNA, and nephrotic syndrome. SLE patients with renal disease had higher levels of circulating SAPhiTPH, and the association between SAPhiTPH and LN remained significant after adjusting for age, sex, race, low complements, and elevated anti-dsDNA (p=0.02).(Fig. 1B)To validate these findings we used the AMP scRNA-Seq data. Using the authors’ clustering analysis, we found a small but statistically significant increase in SAP levels from renal infiltrating T cells from SLE compared with control kidney biopsy samples (p=0.03). Notably, SAP expression in CD4 T cells was differentially upregulated in the TFH-like vs. the T-regulatory subsets in the SLE vs. control group. (Fig. 2)

Conclusion: We identified that SAPhiTPH cells are associated with active SLE, specifically LN. Furthermore, we validated the presence of an analogous SAPhi TFH-like subset in the LN kidney biopsy samples, suggesting direct tissue-level infiltration by these cells. Future work to improve our understanding of SAP functions and signaling in these cells is likely to reveal novel therapeutic targets in SLE.

Supporting image 1

Patient Characteristics.

Supporting image 2

Figure 1. SAP expression in the T peripheral helper (TPH) CD4 T cells is associated with lupus nephritis. (A) SAP levels are increased in the TPH subset of CD4 T cells isolated from patients with SLE patients. (B)SAPhiTPH cells are expanded in SLE patients with LN compared to SLE patients without LN or in healthy controls (HC).

Supporting image 3

Figure 2. SAP levels are increased in the TFH-like renal infiltrating cells in LN. We analyzed the scRNA-Seq data from the publicly available Accelerated Medicines Partnership in the SLE LN dataset using the authors’ original clustering algorithm. (A) SAP expression in all CD3 positive T cells. (B) Sub-analysis of SAP levels based on the authors’ original T cell clustering algorithm. HC, healthy control. SLE, systemic lupus erythematosus.


Disclosures: Y. Gartshteyn: None; L. Khalili: None; L. Geraldino-Pardilla: None; A. Mor: None; A. Askanase: AbbVie, 2, Amgen, 2, AstraZeneca, 2, Aurinia, 2, Bristol-Myers Squibb, 2, Celgene, 2, Eli Lilly, 2, Genentech, 2, GSK, 2, Idorsia, 2, Janssen, 2, Mallinckrodt, 2, Pfizer, 2, UCB Pharma, 2.

To cite this abstract in AMA style:

Gartshteyn Y, Khalili L, Geraldino-Pardilla L, Mor A, Askanase A. SAPhigh T Peripheral Helper Cells Are a Novel Subset Associated with Lupus Nephritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/saphigh-t-peripheral-helper-cells-are-a-novel-subset-associated-with-lupus-nephritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/saphigh-t-peripheral-helper-cells-are-a-novel-subset-associated-with-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology